Pfizer says sales of its Covid vaccine will hit $36bn this year

Pfizer has said it believes sales of its Covid vaccine will hit $36bn this year and predicted another $29bn next year.

The pharmaceutical company, whose vaccine is being used to deliver Covid booster jabs in the UK, revealed its projected sales figures yesterday. Its 2021 and 2022 figures are the equivalent of around £26.3bn and £21bn respectively.

This year’s figure would make up around 44 per cent of Pfizer’s total revenue for 2021 and the company is looking to sign agreements with more countries to supply the vaccine, potentially driving up its revenue further and bolstered by the ability to deliver four billion doses next year.

Pfizer splits its expenses and profits from the vaccine with the German company BioNTech who it partnered with to develop the vaccine.

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to P3 Pharmacy's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.